Ann Dermatol.  2011 Dec;23(Suppl 3):S383-S386. 10.5021/ad.2011.23.S3.S383.

Maximal Points of Head's Zone in Fixed Drug Eruption

Affiliations
  • 1Department of Dermatology, College of Medicine, Chungnam National University, Daejeon, Korea. jhoon@cnu.ac.kr

Abstract

The principles determining the primary localization of lesions in fixed drug eruption (FDE) are still unknown. Studies investigating the predilection areas in FDE have indicated drug-related, trauma-related, or inflammation-related specific site involvement, as well as visceracutaneous reflex-related specific site involvement. The importance of viscerocutaneous reflexes for the location of dermatoses was first recognized in the 1960s. Head's zones are viscerocutaneous reflex projection fields on the skin that extend over certain dermatomes and possess a reflex-associated maximal point. Recently, in a Turkish collective of patients, three women with the primary location of FDE lesions on the maximal points of Head's zones were presented. We also experienced 3 cases with FDE where the lesions were located at specific sites (buttocks), the so-called maximal points of Head's zones, which are known to be the most active dermatomal areas of an underlying visceral pathology. An underlying internal disturbance (ureter stone, pyelonephritis and chronic pelvic inflammatory disease) was found in all 3 patients, corresponding to the organ-related maximal point of Head's zones in each case. In conclusion, the primary location of FDE lesions on the maximal points of Head's zones revealed relevant organ disorders with corresponding projection fields.

Keyword

Fixed drug eruption; Maximal points of Head's zone; Viscerocutaneous refle

MeSH Terms

Drug Eruptions
Female
Humans
Pyelonephritis
Reflex
Skin
Skin Diseases

Figure

  • Fig. 1 Case 1. Thiazide-induced fixed drug eruption on lumbar 2-maximal point. Right ureter stone (corresponding Head's zones for ureter: Th9-L3).

  • Fig. 2 Case 2. Ciprofloxacin-induced fixed drug eruption on lumbar 2-maximal point. Right chronic pyelonephritis (corresponding Head's zones for kidney: Th9-L3).

  • Fig. 3 Case 3. Doxycycline-induced fixed drug eruption on lumbar 2-maximal point. Chronic pelvic inflammatory disease (corresponding Head's zones for uterus and adnexes: Th10-L4).


Reference

1. Thankappan TP, Zachariah J. Drug-specific clinical pattern in fixed drug eruptions. Int J Dermatol. 1991. 30:867–870.
Article
2. Sharma VK, Dhar S, Gill AN. Drug related involvement of specific sites in fixed eruptions: a statistical evaluation. J Dermatol. 1996. 23:530–534.
Article
3. Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol. 2003. 49:1003–1007.
Article
4. Kanwar AJ, Kaur S, Nanda A, Sharma R. Fixed drug eruption at the site of BCG vaccination. Pediatr Dermatol. 1988. 5:289.
Article
5. Mizukawa Y, Shiohara T. Trauma-localized fixed drug eruption: involvement of burn scars, insect bites and venipuncture sites. Dermatology. 2002. 205:159–161.
Article
6. Ozkaya E. Fixed drug eruption: primary site involvement on maximal points of Head's zones. Acta Derm Venereol. 2007. 87:517–520.
Article
7. Hansen K, Schliack H, editors. Segmentale Innervation. Ihre Bedeutung für Klinik und Praxis. 1962. Stuttgart: Thieme.
8. Roche Lexicon Medizin. 1987. 2nd ed. München: Urban & Schwarzenberg;744.
9. Hauser W. Korting GW, editor. Lokalisationsproblem bei Hautkrankheiten. Dermatologie in Praxis und Klinik. 1980. Stuttgart: Thieme;8.60–8.93.
10. Mizukawa Y, Yamazaki Y, Teraki Y, Hayakawa J, Hayakawa K, Nuriya H, et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol. 2002. 161:1337–1347.
Article
11. Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol. 2002. 2:317–323.
Article
12. Teraki Y, Shiohara T. IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol. 2003. 112:609–615.
Article
13. Sehgal VN, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol. 2006. 45:897–908.
Article
14. Korkij W, Soltani K. Fixed drug eruption. A brief review. Arch Dermatol. 1984. 120:520–524.
Article
15. Shiohara T, Mizukawa Y. The immunological basis of lichenoid tissue reaction. Autoimmun Rev. 2005. 4:236–241.
Article
16. Lett A, editor. Reflex zone therapy for health professionals. 2000. Oxford: Churchill Livingstone.
17. Stüttgen G. Reflex therapy in dermatology. Clin Dermatol. 1999. 17:77–91.
Article
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr